The potentially modifiable risk factor in idiopathic intracranial hypertension: body weight

Research output: Contribution to journalArticlepeer-review

86 Downloads (Pure)


Purpose of review: Idiopathic intracranial hypertension (IIH) prevalence increased in conjunction with rising obesity rates. Here, we highlight the importance of weigh management in IIH, and introduce glucagon-like peptide 1 (GLP-1) receptor agonists (RA) as potential treatment strategy for IIH.

Recent findings: Weight gain is a risk factor for IIH; and weight loss (via any treatment strategy) plays a key role in IIH management. GLP-1 is an incretin secreted by the distal small intestine in response to a meal. GLP-1 RA have been shown to improve glycaemic control (no. hypoglycaemia) and lower body weight in patients with and without type 2 diabetes. The choroid plexus has been found to express GLP-1 receptors and treatment with a GLP-1 RA significantly reduces cerebrospinal fluid secretion in vitro and intracranial pressure in rodents.

Summary: New research evaluating the pathophysiology of IIH supports GLP-1 RA as a potential treatment for IIH via weight loss dependant and independent mechanism to directly reduce intracranial pressure.
Original languageEnglish
JournalNeurology: Clinical Practice
Early online date3 Mar 2021
Publication statusE-pub ahead of print - 3 Mar 2021


Dive into the research topics of 'The potentially modifiable risk factor in idiopathic intracranial hypertension: body weight'. Together they form a unique fingerprint.

Cite this